参考文献/References:
［1］ OLAYIOYE M A，NEVE R M，LANE H A，et al.The ErbB signaling network：receptor heterodimerization in development and cancer［J］.EMBO J，2000，19（13）：3159-3167.
［2］ BERGER M B，MENDROLA J M，LEMMON M A.ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface［J］.FEBS Lett，2004，569（1/3）：332-336.
［3］ YARDEN Y，SLIWKOWSKI M X.Untangling the ErbB signalling network［J］.Nat Rev Mol Cell Biol，2001，2（2）：127-137.
［4］ BEERLI R R，HYNES N E.Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities［J］.J Biol Chem，1996，271（11）：6071-6076.
［5］ KARUNAGARAN D，TZAHAR E，BEERLI R R，et al.ErbB-2 is a common auxiliary subunit of NDF and EGF receptors：implications for breast cancer［J］.EMBO J，1996，15（2）：254-264.
［6］ SPENCER K S，GRAUS-PORTA D，LENG J，et al.ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases［J］.J Cell Biol，2000，148（2）：385-397.
［7］ HELLYER N J，CHENG K，KOLAND J G.ErbB3 （HER3） interaction with the p85 regulatory subunit of phosphoinositide 3-kinase［J］.Biochem J，1998，333 （Pt 3）：757-763.
［8］ PRIGENT S A，GULLICK W J.Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera［J］.EMBO J，1994，13（12）：2831-2841.
［9］ SERGINA N V，RAUSCH M，WANG D，et al.Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3［J］.Nature，2007，445（7126）：437-441.
［10］ FENG S M，SARTOR C I，HUNTER D，et al.The HER4 cytoplasmic domain，but not its C terminus，inhibits mammary cell proliferation［J］.Mol Endocrinol，2007，21（8）：1861-1876.
［11］ YU D，HUNG M C.Role of ErbB2 in breast cancer chemosensitivity［J］.Bioessays，2000，22（7）：673-680.
［12］ SLAMON D J，GODOLPHIN W，JONES L A，et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer［J］.Science，1989，244（4905）：707-712.
［13］ SLAMON D J，CLARK G M，WONG S G，et al.Human breast cancer：correlation of relapse and survival with amplification of the HER-2/neu oncogene［J］.Science，1987，235（4785）：177-182.
［14］ LIN Y Z，CLINTON G M.A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells［J］.Oncogene，1991，6（4）：639-643.
［15］ LEITZEL K，TERAMOTO Y，KONRAD K，et al.Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer［J］.J Clin Oncol，1995，13（5）：1129-1135.
［16］ CHRISTIANSON T A，DOHERTY J K，LIN Y J，et al.NH2-terminally truncated HER-2/neu protein：relationship with shedding of the extracellular domain and with prognostic factors in breast cancer［J］.Cancer Res，1998，58（22）：5123-5129.
［17］ COLOMER R，MONTERO S，LLUCH A，et al.Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer［J］.Clin Cancer Res，2000，6（6）：2356-2362.
［18］ BERCHUCK A，KAMEL A，WHITAKER R，et al.Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer［J］.Cancer Res，1990，50（13）：4087-4091.
［19］ TAN M，YAO J，YU D.Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities［J］.Cancer Res，1997，57（6）：1199-1205.
［20］ NEVE R M，SUTTERLUTY H，PULLEN N，et al.Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells［J］.Oncogene，2000，19（13）：1647-1656.
［21］ BEERLI R R，GRAUS-PORTA D，WOODS-COOK K，et al.Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2［J］.Mol Cell Biol，1995，15（12）：6496-6505.
［22］ DREBIN J A，LINK V C，STERN D F，et al.Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies［J］.Cell，1985，41（3）：697-706.
［23］ HUDZIAK R M，LEWIS G D，WINGET M，et al.p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor［J］.Mol Cell Biol，1989，9（3）：1165-1172.
［24］ CARTER P，PRESTA L，GORMAN C M，et al.Humanization of an anti-p185HER2 antibody for human cancer therapy［J］.Proc Natl Acad Sci USA，1992，89（10）：4285-4289.
［25］ CHO H S，MASON K，RAMYAR K X，et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab［J］.Nature，2003，421（6924）：756-760.
［26］ DI MODICA M，SFONDRINI L，REGONDI V，et al.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition［J］.Oncotarget，2016，7（1）：255-265.
［27］ YOU B，CHEN E X.Anti-EGFR monoclonal antibodies for treatment of colorectal cancers：development of cetuximab and panitumumab［J］.J Clin Pharmacol，2011，52（2）：128-155.
［28］ POZZI C，CUOMO A，SPADONI I，et al.The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death［J］.Nat Med，2016，22（6）：624-631.
［29］ CHUNG C H，MIRAKHUR B，CHAN E，et al.Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1，3-galactose［J］.N Engl J Med，2008，358（11）：1109-1117.
［30］ DE TURSI M，ZILLI M，CARELLA C，et al.Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer：a new tool for more accurate comprehension of quality of life impacts［J］.Onco Targets Ther，2017，10：3007-3015.
［31］ WANG C，HE X，ZHOU B，et al.Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors［J］.MAbs，2011，3（1）：67-75.
［32］ CAPDEVILA J，ELEZ E，MACARULLA T，et al.Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment［J］.Cancer Treat Rev，2009，35（4）：354-363.
［33］ PATEL S B，GILL D，GARRIDO-LAGUNA I.Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer［J］.Onco Targets Ther，2016，9：75-86.
［34］ MONTAGUT C，DALMASES A，BELLOSILLO B，et al.Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer［J］.Nat Med，2012，18（2）：221-223.
［35］ SICKMIER E A，KURZEJA R J，MICHELSEN K，et al.The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance［J］.PLoS One，2016，11（9）：e0163366.
［36］ BABA Y，TAMURA T，SATOH Y，et al.Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine［J］.Mol Oncol，2017，11（8）：1065-1077.
相似文献/References:
[1]张世魁,李景艳,梅家转.NKG2D-NKG2D配体系统抗肿瘤作用研究进展[J].新乡医学院学报,2017,34(1):079.[doi:10.7683/xxyxyxb.2017.01.023]
[2]王瑶,李铁鹏,何美颉,等.肿瘤免疫检查点抑制剂联合过继性细胞免疫治疗研究进展[J].新乡医学院学报,2022,39(10):988.[doi:10.7683/xxyxyxb.2022.10.017]
WANG Yao,LI Tiepeng,HE Meijie,et al.Research progress of tumor immune checkpoint inhibitor combined with adoptive cellular immunotherapy[J].Journal of Xinxiang Medical University,2022,39(10):988.[doi:10.7683/xxyxyxb.2022.10.017]